State Street SPDR S&P Biotech ETF
738 hedge funds and large institutions have $9.85B invested in State Street SPDR S&P Biotech ETF in 2024 Q4 according to their latest regulatory filings, with 103 funds opening new positions, 193 increasing their positions, 282 reducing their positions, and 117 closing their positions.
26.88% more ownership
Funds ownership: 129.89% → 156.78% (+27%)
3% less capital invested
Capital invested by funds: $10.2B → $9.85B (-$318M)
4% less funds holding
Funds holding: 769 → 738 (-31)
12% less first-time investments, than exits
New positions opened: 103 | Existing positions closed: 117
24% less funds holding in top 10
Funds holding in top 10: 21 → 16 (-5)
32% less repeat investments, than reductions
Existing positions increased: 193 | Existing positions reduced: 282
38% less call options, than puts
Call options by funds: $2.07B | Put options by funds: $3.32B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$860M |
| 2 |
Citigroup
New York
|
+$330M |
| 3 |
DFG
Demars Financial Group
Spokane Valley,
Washington
|
+$302M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$212M |
| 5 |
Morgan Stanley
New York
|
+$208M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$413M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$394M |
| 3 |
Goldman Sachs
New York
|
-$309M |
| 4 |
CI Investments Inc
Toronto,
Ontario, Canada
|
-$104M |
| 5 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$86.8M |
XBI Hedge Fund Activity: Q4 2024 in Review
738 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q4 2024, worth a combined $9.85B — down 3.1% from $10.2B a quarter earlier.
Sellers outnumbered buyers: 117 funds closed out of XBI and 103 opened new positions — a net loss of 14 holders — while 282 trimmed existing stakes and 193 added.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $860M. The largest seller was JP Morgan Chase, cutting an estimated $413M.
- 738 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q4 2024, down from 769 in Q3 2024.
- Funds reported $9.85B of State Street SPDR S&P Biotech ETF stock for Q4 2024, down 3.1% quarter-over-quarter.
- 103 funds opened new State Street SPDR S&P Biotech ETF positions in Q4 2024 and 117 closed out, a net change of -14 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q4 2024 was BNP Paribas Financial Markets, an estimated $860M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q4 2024 was JP Morgan Chase, an estimated $413M sold.
Based on aggregated 13F filings for Q4 2024.